14-11-2022 | ACR 2022 | Conference coverage | News
Addition of the recombinant fusion protein telitacicept to standard care may reduce disease activity and is well tolerated in people with systemic lupus erythematosus, research suggests.
01-11-2022 | Systemic lupus erythematosus | News
Dapagliflozin deserves further study as an add-on therapy for reducing renal and cardiovascular risk in patients with systemic lupus erythematosus, suggest preliminary trial findings.
01-09-2022 | Cardiovascular disease | News
A large study published in The Lancet has found that people with autoimmune diseases have an approximately 1.4–3.6-fold increased risk for developing cardiovascular disease relative to the general population.